A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Molecular Therapy

Topics

Medicine

Cancer Oncology

Epidemiology

Immunology

Internal Medicine

Show all topics

DOI

10.1038/mt.2014.22

License

CC-BY-NC-ND

Other Formats

PDF